More on Multiple Myeloma From ASCO 2023 Focus on Bispecific ...

Myeloma Matters: Bispecific Antibody Horizons: Dosing

This podcast reviews highlights from the 2024 ASCO and EHA annual meetings, including information about fixed-duration dosing to mitigate ...

(PDF) Bispecific antibodies and dual-targeting CAR-T cells for ...

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting ; August 2023 ...

Unlocking the potential of targeted therapies for multiple myeloma

Targeted therapies offer new hope for MM patients. The review highlights the impressive progress made in developing monoclonal antibodies, ADCs, ...

ASCO 2023: Janssen reports positive results for Talquetamab in ...

The company reported results for the bispecific antibody form Phase I studies in patients with relapsed or refractory multiple myeloma.

Abstracts & Presentations - ASCO Meeting Program Guide

... bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). ... 2023 ASCO Annual Meeting - Poster Session ...

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ...

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023 ... multiple myeloma: Phase 1/ ...

The Latest in Multiple Myeloma - The Patient Story

Learn about new multiple myeloma treatment options, including triplet and quadruplet combination therapies, CAR T-cell therapy, bispecific antibodies, and ...

SOCIAL MEDIA IMPACT of ASCO 2023 - APLUSA

... asco NEAR/2 (2023 OR ... Focus on multiple myeloma. This year's edition was heavily focused on CAR-T cell therapies and bispecific antibodies.

ESMO 2023 – Merus gets a pre-meeting boost - Oncology Pipeline

... more data and advised Merus to focus on lung and pancreatic cancers. ... ASH 2024 preview – multiple myeloma in focus. 08 November 2024. ASH ...

Safety and efficacy of T-cell-redirecting bispecific antibodies for ...

Multiple myeloma (MM) is the second most frequent hematological malignancy around the world [1]. The disease is characterized by the ...

ASCO: J&J's subcutaneous bispecifics tackle multiple myeloma in ...

The drugmaker revealed phase 1 data for two bispecific antibodies showing they shrank the tumors of about 70% of patients whose cancer got worse despite trying ...

ASCO: Multiple Myeloma Wrap Up - Patient Power

From the 2023 American Society of Clinical Oncologist (ASCO) annual meeting, Hans Lee, MD, from MD Anderson Cancer Center, joins Patient ...

ASH Highlights on Multiple Myeloma - Medimix Hematology

share his highlights on multiple myeloma from ASH 2023. The EMN 17 Perseus study, focusing on frontline intervention in transplant-eligible patients with MM ...

Bispecific Antibodies in Multiple Myeloma: Present and Future.

Bispecific antibodies are designed to bind both a target on the malignant plasma cells and on cytotoxic immune effector cells [T cells/natural killer (NK) cells] ...

New Data on BCMA-Directed Bispecifics in Multiple Myeloma

This third of four exclusive episodes on multiple myeloma focuses on treatment with BCMA bispecific antibodies. Following is a transcript of ...

An Uncertain Road Lies Ahead for Allogeneic Cell Therapy - Health ...

... more lines of therapy, is ... multiple myeloma presents high potential for bispecific combination therapy. ... References. ASCO 2023; Cappell 2023 Nature Rev.

Regeneron, Pfizer Tout Potential BCMA Bispecific Advantages At ...

As the field of BCMA-directed bispecific antibodies in multiple myeloma grows more crowded, the question of how to position them on the market is becoming ...

IMWG Conference Series: ASCO & EHA 2023 - YouTube

At the IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts will discuss the latest drug therapy news from the June ...

HTML Sitemap - Patient Power

What's New for Multiple Myeloma at ASCO 2024? ASCO 2024: “We Should Be Using ... More · Nina DiPierro, PharmD, BCOP · Bispecific Antibody Combos for R/R Myeloma.

Bispecific antibody drives myeloma precursor condition to ...

In the first clinical trial of an immunotherapy agent for people with high-risk smoldering myeloma (HR-SMM) – a precursor of multiple ...